RxDoctor Payments DataLook up a doctor →

Ronald Mittel, MD

Allergy & Immunology · Peoria, AZNPI 1407016348

Payments from drug & device makers

$22,978in general payments, 2019–2025

Across 1,103 payments — averaging $20.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron Healthcare Solutions, Inc.$3K
  • GSK$3K
  • AstraZeneca$3K
  • Sanofi$2K
  • Optinose US, Inc.$1K
  • CSL Behring$1K
  • plus $10K from 45 others

What the payments were for

  • Consulting fees$2,73712%
  • Food & beverage$20,14888%
  • Education$930%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$22,978 in reported general payments places this provider in the 75th percentile of 90 allergy & immunology providers in Arizona.

See all allergy & immunology providers in Arizona

Medicare billing

Part B allowed, 2024
$294,260
Medicare patients
397
Services billed
14,754

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent SyringeDupilumab65$271,049
CuvitruImmun Glob G(Igg)/Gly/Iga Ov5027$104,115
Dupixent PenDupilumab14$51,873
Trelegy ElliptaFluticasone/Umeclidin/Vilanter56$43,114
Breztri AerosphereBudesonide/Glycopyr/Formoterol32$26,328
Spiriva RespimatTiotropium Bromide26$22,957
Breo ElliptaFluticasone/Vilanterol34$22,944
XhanceFluticasone Propionate21$18,078
Azelastine Hcl308$11,846
Epinephrine59$9,913
Arnuity ElliptaFluticasone Furoate17$4,993
SymbicortBudesonide/Formoterol Fumarate12$4,616
Albuterol Sulfate HfaAlbuterol Sulfate135$4,278
Ipratropium Bromide124$3,260
Fluticasone-SalmeterolFluticasone Propion/Salmeterol19$2,783

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Cuvitru$1,138$104,11527 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$2,556$71,050107 claims
AstraZenecaBreztri Aerosphere, Symbicort$2,509$30,94444 claims
Boehringer IngelheimSpiriva Respimat$389$22,95726 claims
Optinose US, Inc.Xhance$1,466$18,07821 claims
Hikma Pharmaceuticals USAEpinephrine$36$9,91359 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 90 allergy & immunology providers in Arizona.

Other allergy & immunology in Peoria

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →